v3.25.4
Segment Information - Summary of Financial Data for Development of Pharmaceutical Products Segments (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Dec. 31, 2025
Sep. 30, 2025
Dec. 31, 2024
Sep. 30, 2024
Dec. 31, 2025
Dec. 31, 2024
Jun. 30, 2025
Operating and other (income) expense              
Employee expenses $ 499   $ 2,076   $ 1,078 $ 6,999  
Other segment expenses 851 [1]   389 [2]   1,687 [3] 1,671 [4]  
Professional fees 728   297   1,499 911  
Legal fees 560   717   1,006 1,186  
Asset management fee and advisory fees 690       1,163    
Change in fair value of digital assets 26,516 $ 631 0   27,147 0  
Change in fair value of digital assets receivable, net 1,533   0   1,533 0  
Gain on disposition of nonfinancial asset 0   (500)   0 (500)  
Gain on derivative liabilities (541)   0   (541) 0  
Interest and dividend income (60) [5]   (279) [6]   (160) [7] (634) [8]  
Total operating and other (income) expense 30,799   2,677   34,438 10,684  
Net (loss) income (30,799) (3,639) (2,677) $ (8,007) (34,438) (10,684)  
Current assets:              
Cash and cash equivalents 8,758       8,758   $ 18,011
Prepaid expenses and other current assets 2,154       2,154   274
Total current assets 10,912       10,912   18,285
Digital assets 63,970 $ 99,369     63,970   0
Digital assets - receivable, net 7,350       7,350    
Other long-term assets 705       705   0
Total assets 82,937       82,937   18,285
voruciclib              
Operating and other (income) expense              
Other segment expenses 23   81   26 798  
ME-344              
Operating and other (income) expense              
Other segment expenses     (104)     253  
Operating Segments [Member]              
Operating and other (income) expense              
Employee expenses 167       399    
Other segment expenses 13 [1]       38 [3]    
Professional fees 371       443    
Legal fees 177       478    
Asset management fee and advisory fees 690       1,163    
Change in fair value of digital assets 26,516       27,147    
Change in fair value of digital assets receivable, net 1,533       1,533    
Gain on derivative liabilities (541)       (541)    
Interest and dividend income 0 [5]       0 [7]    
Total operating and other (income) expense 28,949       30,686    
Net (loss) income (28,949)       (30,686)    
Current assets:              
Cash and cash equivalents 0       0    
Prepaid expenses and other current assets 1,112       1,112    
Total current assets 1,112       1,112    
Digital assets 63,970       63,970    
Digital assets - receivable, net 7,350       7,350    
Other long-term assets 0       0    
Total assets 72,432       72,432    
Operating Segments [Member] | Digital Asset Treasury Strategy              
Operating and other (income) expense              
Employee expenses 144       376    
Other segment expenses 13 [1]       33 [3]    
Professional fees 371       441    
Legal fees 5       112    
Asset management fee and advisory fees 690       1,163    
Change in fair value of digital assets 26,516       27,147    
Change in fair value of digital assets receivable, net 1,533       1,533    
Gain on derivative liabilities (541)       (541)    
Interest and dividend income 0 [5]       0 [7]    
Total operating and other (income) expense 28,731       30,264    
Net (loss) income (28,731)       (30,264)    
Current assets:              
Cash and cash equivalents 0       0    
Prepaid expenses and other current assets 1,061       1,061    
Total current assets 1,061       1,061    
Digital assets 63,970       63,970    
Digital assets - receivable, net 7,350       7,350    
Other long-term assets 0       0    
Total assets 72,381       72,381    
Operating Segments [Member] | Development of Pharmaceutical Products              
Operating and other (income) expense              
Employee expenses 23   401   23 2,366  
Other segment expenses 0 [1]   (79) [2]   5 [3] 33 [4]  
Professional fees 0   9   2 21  
Legal fees 172   212   366 409  
Asset management fee and advisory fees 0       0    
Change in fair value of digital assets 0       0    
Change in fair value of digital assets receivable, net 0       0    
Gain on disposition of nonfinancial asset     0     0  
Gain on derivative liabilities 0       0    
Interest and dividend income 0 [5]   0 [6]   0 [7] 0 [8]  
Total operating and other (income) expense 218   520   422 3,880  
Net (loss) income (218)   (520)   (422) (3,880)  
Current assets:              
Cash and cash equivalents 0       0   0
Prepaid expenses and other current assets 51       51   25
Total current assets 51       51   25
Digital assets 0       0    
Digital assets - receivable, net 0       0    
Other long-term assets 0       0    
Total assets 51       51   25
Operating Segments [Member] | voruciclib              
Operating and other (income) expense              
Other segment expenses 23       26    
Operating Segments [Member] | voruciclib | Digital Asset Treasury Strategy              
Operating and other (income) expense              
Other segment expenses 0       0    
Operating Segments [Member] | voruciclib | Development of Pharmaceutical Products              
Operating and other (income) expense              
Other segment expenses 23   81   26 798  
Operating Segments [Member] | ME-344 | Development of Pharmaceutical Products              
Operating and other (income) expense              
Other segment expenses     (104)     253  
Corporate [Member]              
Operating and other (income) expense              
Employee expenses 332   1,675   679 4,633  
Other segment expenses 838 [1]   468 [2]   1,649 [3] 1,638 [4]  
Professional fees 357   288   1,056 890  
Legal fees 383   505   528 777  
Asset management fee and advisory fees 0       0    
Change in fair value of digital assets 0       0    
Change in fair value of digital assets receivable, net 0       0    
Gain on disposition of nonfinancial asset     (500)     (500)  
Gain on derivative liabilities 0       0    
Interest and dividend income (60) [5]   (279) [6]   (160) [7] (634) [8]  
Total operating and other (income) expense 1,850   2,157   3,752 6,804  
Net (loss) income (1,850)   (2,157)   (3,752) (6,804)  
Current assets:              
Cash and cash equivalents 8,758       8,758   18,011
Prepaid expenses and other current assets 1,042       1,042   249
Total current assets 9,800       9,800   18,260
Digital assets 0       0    
Digital assets - receivable, net 0       0    
Other long-term assets 705       705    
Total assets 10,505       10,505   $ 18,260
Corporate [Member] | voruciclib              
Operating and other (income) expense              
Other segment expenses $ 0   0   $ 0 0  
Corporate [Member] | ME-344              
Operating and other (income) expense              
Other segment expenses     $ 0     $ 0  
[1] Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs, share-based compensation costs, administrative costs, travel and business taxes.
[2] Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs (including rent and utilities), share-based compensation costs, depreciation expense, administrative costs, travel and business taxes.
[3] Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs, share-based compensation costs, administrative costs, travel and business taxes.
[4] Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs (including rent and utilities), share-based compensation costs, depreciation expense, administrative costs, travel and business taxes.
[5] Interest and dividend income are solely attributable to our cash and cash equivalents.
[6] Interest and dividend income are solely attributable to our cash and cash equivalents.
[7] Interest and dividend income are solely attributable to our cash and cash equivalents.
[8] Interest and dividend income are solely attributable to our cash and cash equivalents.